In this study the off-target anti-VEGF/PDGF therapy generated a synergistical effect in which PDGF inhibition ablated bFGF-dependent perivascular coverage which further sensitized tumor vessels to anti-VEGF inhibition. The gene discussed is FGF2; the disease is neoplasm.